MX2020003504A - Receptores de celulas t que reconocen p53 mutado. - Google Patents

Receptores de celulas t que reconocen p53 mutado.

Info

Publication number
MX2020003504A
MX2020003504A MX2020003504A MX2020003504A MX2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A MX 2020003504 A MX2020003504 A MX 2020003504A
Authority
MX
Mexico
Prior art keywords
cell receptors
mammal
methods
receptors recognizing
mutated
Prior art date
Application number
MX2020003504A
Other languages
English (en)
Inventor
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Drew C Deniger
Anna Pasetto
Winifred M Lo
Yong-Chen Lu
Maria R Parkhurst
Parisa Malekzadeh
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2020003504A publication Critical patent/MX2020003504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Se describe un receptor de células T (TCR) aislado o purificado que tiene especificidad antigénica para p53 humano mutado. También se proporcionan polipéptidos y proteínas relacionadas, así como ácidos nucleicos, vectores de expresión recombinante, células hospedadoras, poblaciones de células y composiciones farmacéuticas relacionadas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir cáncer en un mamífero.
MX2020003504A 2017-09-29 2018-09-17 Receptores de celulas t que reconocen p53 mutado. MX2020003504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (1)

Publication Number Publication Date
MX2020003504A true MX2020003504A (es) 2020-09-14

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003504A MX2020003504A (es) 2017-09-29 2018-09-17 Receptores de celulas t que reconocen p53 mutado.

Country Status (15)

Country Link
US (1) US11939365B2 (es)
EP (1) EP3688027A1 (es)
JP (2) JP7324193B2 (es)
KR (1) KR20200064110A (es)
CN (1) CN111386282A (es)
AU (1) AU2018342246A1 (es)
BR (1) BR112020006012A2 (es)
CA (1) CA3077024A1 (es)
CR (1) CR20200170A (es)
EA (1) EA202090757A1 (es)
IL (1) IL273515A (es)
MA (1) MA50651A (es)
MX (1) MX2020003504A (es)
SG (1) SG11202002636PA (es)
WO (1) WO2019067243A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534051A (ja) * 2019-05-27 2022-07-27 プロビンシャル・ヘルス・サービシーズ・オーソリティ Ｋｒａｓ抗原を標的とする免疫療法コンストラクト
WO2020264269A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
AU2021336399A1 (en) * 2020-09-04 2023-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
EP4298121A1 (en) 2021-02-25 2024-01-03 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
CA3217263A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Depart... T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
ATE405582T1 (de) * 2001-06-05 2008-09-15 Altor Bioscience Corp P53 bindende t-zellrezeptormoleküle und deren verwendungen
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2920147C (en) * 2013-08-07 2022-09-20 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
KR102375998B1 (ko) * 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
PL3149031T3 (pl) 2014-05-29 2020-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Receptory limfocytów t przeciwko e7 wirusa brodawczaka ludzkiego 16
CN107074932A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
AU2014407540C1 (en) 2014-10-02 2021-07-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
CA2978628A1 (en) 2015-03-03 2016-09-09 Caris Mpi, Inc. Molecular profiling for cancer
CA2984234C (en) * 2015-05-01 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens

Also Published As

Publication number Publication date
SG11202002636PA (en) 2020-04-29
WO2019067243A1 (en) 2019-04-04
EA202090757A1 (ru) 2020-08-21
JP7324193B2 (ja) 2023-08-09
CR20200170A (es) 2020-11-23
AU2018342246A1 (en) 2020-04-16
MA50651A (fr) 2020-08-05
CA3077024A1 (en) 2019-04-04
JP2021500010A (ja) 2021-01-07
EP3688027A1 (en) 2020-08-05
KR20200064110A (ko) 2020-06-05
US20200277352A1 (en) 2020-09-03
US11939365B2 (en) 2024-03-26
CN111386282A (zh) 2020-07-07
IL273515A (en) 2020-05-31
JP2023159112A (ja) 2023-10-31
BR112020006012A2 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
EA202092044A1 (ru) Химерные рецепторы антигена против cd33 и их применения
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
CY1124558T1 (el) Προβλεψη επιτοπων τ κυτταρων χρησιμων για εμβολιασμο
CY1122676T1 (el) Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
MX2017006865A (es) Receptores de células t de kras anti-mutado.
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
EA202192126A3 (ru) Способы сбора культур клеток млекопитающих
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
EA201791918A1 (ru) Модификация белков клеток-хозяев
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
MX2018003445A (es) Expresion de proteinas que contienen fc.
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
BR112019004017A2 (pt) proteínas quiméricas para direcionar dsrna